Drugs / DR30206
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06132828 | Nov 2023 → Jul 2027 expected | cancer | Zhejiang Doer Biologics Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07056777 | Mar 2025 → Apr 2027 expected | digestive system cancer | Zhejiang Doer Biologics Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DR30206 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06132828 ↗ |
| Route | Intravenous | “Subjects receive DR30206 intravenously” NCT06132828 ↗ |